Artiva Biotherapeutics
ARTV
40 hedge funds and large institutions have $52.1M invested in Artiva Biotherapeutics in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 16 reducing their positions, and 14 closing their positions.
3% more capital inflows, than outflows
Capital inflows: $2.91M | Capital outflows: $2.83M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.65% less ownership
Funds ownership: 75.97% → 74.32% (-1.6%)
17% less funds holding
Funds holding: 48 → 40 (-8)
50% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 16
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.72M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$315K |
| 3 |
Citigroup
New York
|
+$273K |
| 4 |
Renaissance Technologies
New York
|
+$212K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$128K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$512K |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$440K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$428K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$198K |
| 5 |
Goldman Sachs
New York
|
-$183K |
ARTV Hedge Fund Activity: Q3 2025 in Review
40 of the 7,647 institutional investors tracked by Wall St. Rank reported a position in Artiva Biotherapeutics (ARTV) for Q3 2025, worth a combined $52.1M — up 86% from $27.9M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ARTV and 6 opened new positions — a net loss of 8 holders — while 16 trimmed existing stakes and 8 added.
The largest buyer was Citadel Advisors, adding an estimated $1.72M. The largest seller was BlackRock, cutting an estimated $512K.
- 40 institutional investors held Artiva Biotherapeutics (ARTV) as of Q3 2025, down from 48 in Q2 2025.
- Funds reported $52.1M of Artiva Biotherapeutics stock for Q3 2025, up 86% quarter-over-quarter.
- 6 funds opened new Artiva Biotherapeutics positions in Q3 2025 and 14 closed out, a net change of -8 holders.
- The largest Artiva Biotherapeutics buyer in Q3 2025 was Citadel Advisors, an estimated $1.72M added.
- The largest Artiva Biotherapeutics seller in Q3 2025 was BlackRock, an estimated $512K sold.
Based on aggregated 13F filings for Q3 2025.